In the BioHarmony Drug Report Database

"Preview" Icon

Miltefosine

Impavido (miltefosine) is a small molecule pharmaceutical. Miltefosine was first approved as Impavido on 2014-03-19. It is used to treat cutaneous leishmaniasis, leishmaniasis, and visceral leishmaniasis in the USA. It is known to target RAC-alpha serine/threonine-protein kinase.

 

Trade Name

 

Impavido
 

Common Name

 

miltefosine
 

ChEMBL ID

 

CHEMBL125
 

Indication

 

cutaneous leishmaniasis, leishmaniasis, visceral leishmaniasis
 

Drug Class

 

Phosphoro-derivatives

Image (chem structure or protein)

Miltefosine structure rendering